TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.

Clicks: 419
ID: 14030
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #6 of 313 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
A long-term prospective observational safety study is essential to fully characterize the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data using a predefined core dataset.We present a protocol for a safety study comparing dupilumab with other systemic immunomodulating therapies in children and adults with moderate-to-severe atopic eczema to assess the long-term safety risk of these therapies in a routine clinical care setting.We describe a registry-embedded international observational prospective cohort study. Adult and paediatric patients who start treatment with dupilumab or anothersystemic immunomodulating agent for their atopic eczema will be included. The primary endpoint is the incidence of malignancies (excluding non-melanoma skin cancer) compared between the treatment groups. Secondary endpoints include other serious adverse events and adverse events of special interest, such as eye disorders and eosinophilia.This protocol delineates a safety study for dupilumab in adult and paediatric patients with atopic eczema, using a standardized methodological approach across several national registries. The protocol could also be used for other novel systemic immunomodulating therapies and could provide licensing and reimbursement authorities, pharmaceutical companies and clinicians with safety evidence from a routine clinical care setting. This article is protected by copyright. All rights reserved.
Reference Key
bosma2019treatmentthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bosma, A L;Spuls, P I;Garcia-Doval, I;Naldi, L;Prieto-Merino, D;Tesch, F;Apfelbacher, C J;Arents, B W M;Barbarot, S;Baselga, E;Deleuran, M;Eichenfield, L F;Gerbens, L A A;Irvine, A D;Manca, A;Mendes-Bastos, P;Middelkamp-Hup, M A;Roberts, A;Seneschal, J;Svensson, Å;Thyssen, J P;Torres, T;Vermeulen, F M;Vestergaard, C;von Kobyletzki, L B;Wall, D;Weidinger, S;Schmitt, J;Flohr, C;
Journal the british journal of dermatology
Year 2019
DOI
10.1111/bjd.18452
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.